On October 26, 2015 Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), reported an upcoming presentation of preclinical data from a study with the Company’s second generation cyclin dependent kinase (CDK) 2/9 inhibitor, CYC065, at the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), November 5-9, 2015, in Boston (Press release, Cyclacel, OCT 26, 2015, View Source [SID:1234507793]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The study evaluated the molecular rationale and dosing schedule of CYC065 for targeting tumors that are either dependent on sustained expression of CDK9 transcription targets, including Mcl-1 and MYC, or on activation of CDK2 by overexpression of cyclin E.
Details of the presentation are as follows:
Abstract Number: B182
Presentation Title: Molecular Basis for Clinical Development of the Novel CDK2/9 Inhibitor CYC065 in Oncology
Presentation Time: Saturday, November 7, 2015, 12:30 PM – 3:30 PM
Location: Exhibit Hall C-D
Poster Board Number: Poster Session B
Authors: Craig MacKay, Sheelagh Frame, Chiara Saladino, Elizabeth Pohler, Daniella Zheleva, David Blake. Cyclacel Ltd, Dundee, United Kingdom
The abstract can be accessed through the conference website, View Source